Metabolix-3
Technical Monograph
Metabolix-3 is a high-potency investigational triple-agonist. Modeled heavily on current triple-incretin architectures (GIP, GLP-1, and Glucagon Receptor agonism), it is studied for profound systemic metabolic reconfiguration.
Mechanism of Action
Simultaneously agonizes three critical metabolic pathways: GLP-1 (satiety/insulin secretion), GIP (satiety/fat modification), and Glucagon (hepatic lipid burning and basal metabolic rate elevation).
Pharmacological Detail
The addition of glucagon agonism serves as a direct catabolic driver, forcing adipocytes and hepatocytes to mobilize fat for energy while the incretin mechanisms suppress appetite.
Pharmacodynamics
Demonstrates highly synergistic reductions in mass markers, surpassing dual-agonism in preclinical benchmarking.
Pharmacokinetics
Utilizes advanced fatty acid attachment chemistry, ensuring stable plasma concentrations for weekly application frequency.
Preclinical Observations & In Vitro Data
Derived from the foundational pathways documented in TRIUMPH phase trials. Represents state-of-the-art multi-receptor metabolic research. Data cited from published literature.
Abstract Highlights
- Concurrent activation of three metabolic signaling axes
- Observations of unprecedented mass parameter reduction in models
- Glucagon-mediated energy expenditure elevation
- Significant clearance of hepatic steatosis markers documented
Chemical Specifications
Material Handling & Stability
Strict Notice
THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.